Posted by Michael Wonder on 15 Mar 2018
Destiny Pharma announces FDA fast track designation for lead clinical candidate, exeporfinium chloride
15 March 2018 - Destiny Pharma today announces that its lead clinical candidate exeporfinium chloride (XF-73) has been granted Fast Track designation by the US FDA for the prevention of post-surgical staphylococcal infections such as Methicillin Resistant Staphylococcus aureus.
This follows the FDA’s acceptance in February 2018 of an investigational new drug application by the Company for the potentially ground-breaking drug.
Fast track designation is one of a package of measures and incentives available under the FDA’s Qualifying Infectious Disease Product (QIDP) programme, set up to encourage development of novel ant-infective drugs. XF-73 was awarded QIDP status in October 2015.
